How long is a typical ipamorelin cycle?
Preclinical ipamorelin research protocols typically run 4-12 weeks of daily or twice-daily administration. Combined-research protocols pairing with CJC-1295 No DAC often use similar 8-12 week protocol lengths to characterise the cumulative GH-axis pharmacology across the full IGF-1 axis response time course.
What the research literature says
The ipamorelin protocol-length framework is informed by both the original Novo Nordisk research program (Raun, PMID 9849822; Johansen pharmacokinetic study, PMID 9879640) and subsequent investigator-driven studies. The Venkova rodent postoperative-ileus work (PMID 19289567) used shorter acute-pharmacology protocols; the Beck human proof-of-concept trial in postoperative-ileus management used a multi-day perioperative dose framework (PMID 25331030).
For GH-axis-research protocols, the multi-week protocol length is informed by the IGF-1 axis response time course — circulating IGF-1 elevation in response to GH-axis activation typically requires 1-2 weeks to reach steady-state and longer protocols (4-12 weeks) are needed to characterise the integrated tissue-level downstream effects. The combined-research framework with CJC-1295 No DAC (CJC-1295 + Ipamorelin Blend) typically uses 8-12 week protocols.
The dosing-cadence within the protocol (daily vs twice-daily) shapes the pulse-frequency framework but not the overall protocol-length framework. Most research-supply protocols use daily pre-sleep dosing or twice-daily (pre-sleep plus morning fasted) dosing across the full protocol period without cycle on/off breaks.
Why this matters in research context
The 4-12 week protocol length is the operational anchor for most ipamorelin research protocols. Researchers studying acute GH-pharmacology may use shorter protocols; researchers studying integrated GH/IGF-1 axis responses use the longer end of the range. Cycle on/off practice is less common in published research protocols than continuous administration across the full protocol period.
Related compounds
- Ipamorelin 10mg — the compound covered by this answer
- CJC-1295 + Ipamorelin Blend — combined-formulation
Related research questions
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. [PMID 9849822]
- Johansen PB et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998;28(11):1083-1095. [PMID 9879640]
- Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther 2009;329(3):1110-1116. [PMID 19289567]
- Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29(12):1527-1534. [PMID 25331030]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Ipamorelin is sold strictly as a research-grade reagent for laboratory and bench research applications.